ANGLE plc - Asset Resilience Ratio

Latest as of June 2021: 33.24%

ANGLE plc (AGL) has an Asset Resilience Ratio of 33.24% as of June 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of ANGLE plc for a breakdown of total debt and financial obligations.

Liquid Assets

GBX11.55 Million
≈ $1.41K USD Cash + Short-term Investments

Total Assets

GBX34.75 Million
≈ $4.23K USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2004–2020)

This chart shows how ANGLE plc's Asset Resilience Ratio has changed over time. See AGL total equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down ANGLE plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is ANGLE plc worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents GBX0.00 0%
Short-term Investments GBX11.55 Million 33.24%
Total Liquid Assets GBX11.55 Million 33.24%

Asset Resilience Insights

  • Very High Liquidity: ANGLE plc maintains exceptional liquid asset reserves at 33.24% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

ANGLE plc Industry Peers by Asset Resilience Ratio

Compare ANGLE plc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Sonic Healthcare Ltd
AU:SHL
Diagnostics & Research 0.13%
Eurofins-Cerep SA
PA:ALECR
Diagnostics & Research 6.56%
Inoviq Ltd
AU:IIQ
Diagnostics & Research 56.29%
Bcal Diagnostics Ltd
AU:BDX
Diagnostics & Research 0.00%
Imagion Biosystems Ltd
AU:IBX
Diagnostics & Research 150.16%
Integral Diagnostics Ltd
AU:IDX
Diagnostics & Research 0.03%
Australian Clinical Labs Ltd
AU:ACL
Diagnostics & Research 4.11%
Monash Ivf Group Ltd
AU:MVF
Diagnostics & Research 1.60%

Annual Asset Resilience Ratio for ANGLE plc (2004–2020)

The table below shows the annual Asset Resilience Ratio data for ANGLE plc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2020-12-31 42.35% GBX16.54 Million
≈ $2.01K
GBX39.05 Million
≈ $4.75K
-6.74pp
2019-12-31 49.09% GBX15.01 Million
≈ $1.83K
GBX30.57 Million
≈ $3.72K
+27.82pp
2013-04-30 21.27% GBX1.60 Million
≈ $194.67
GBX7.52 Million
≈ $915.31
+24.24pp
2012-04-30 -2.97% GBX-154.00K
≈ $-18.74
GBX5.18 Million
≈ $630.86
+25.58pp
2011-04-30 -28.55% GBX-1.50 Million
≈ $-182.51
GBX5.25 Million
≈ $639.26
+0.12pp
2010-04-30 -28.67% GBX-1.55 Million
≈ $-188.47
GBX5.40 Million
≈ $657.39
-37.83pp
2009-04-30 9.16% GBX499.00K
≈ $60.71
GBX5.45 Million
≈ $663.11
-2.19pp
2008-04-30 11.35% GBX1.04 Million
≈ $126.78
GBX9.18 Million
≈ $1.12K
-12.05pp
2007-04-30 23.40% GBX1.81 Million
≈ $220.47
GBX7.74 Million
≈ $941.98
-6.79pp
2006-04-30 30.20% GBX4.87 Million
≈ $592.29
GBX16.12 Million
≈ $1.96K
0.00pp
2005-04-30 30.20% GBX4.87 Million
≈ $592.29
GBX16.12 Million
≈ $1.96K
+10.31pp
2004-04-30 19.89% GBX2.40 Million
≈ $291.77
GBX12.06 Million
≈ $1.47K
--
pp = percentage points

About ANGLE plc

LSE:AGL UK Diagnostics & Research
Market Cap
$94.18K
GBX774.07 Million GBX
Market Cap Rank
#30999 Global
#1120 in UK
Share Price
GBX2.40
Change (1 day)
-9.43%
52-Week Range
GBX1.75 - GBX10.50
All Time High
GBX156.00
About

ANGLE plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis. It also provides Portrait+ C… Read more